Evidence map›Paper›PMID 28570439›Full record

Observational studyPsychosomatic medicine2017

Cortisol Awakening Response as a Prospective Risk Factor for Depressive Symptoms in Women After Treatment for Breast Cancer.

Kate Ryan Kuhlman, Michael R Irwin, Patricia A Ganz, Catherine M Crespi, Laura Petersen, Arash Asher, Julienne E Bower

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Psychosomatic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kate Ryan KuhlmanFrom the Department of Psychology (Kuhlman, Bower), Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior (Kuhlman, Irwin, Bower), Jonsson Comprehensive Cancer Center (Ganz, Crespi, Petersen, Bower), Department of Biostatistics, Fielding School of Public Health (Crespi), and David Geffen School of Medicine (Irwin, Ganz), University of California Los Angeles; and Samuel Oschin Comprehensive Cancer Institute (Asher), Cedars-Sinai Medical Center, Los Angeles, California.
Michael R Irwin
Patricia A Ganz
Catherine M Crespi
Laura Petersen
Arash Asher
Julienne E Bower
Angeles University Foundation · PH

Funding

PREVENTION RESEARCH TRAINING:URBAN CHILDREN'S MENT HLTHT32MH015750 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHRISTINE DUNKEL SCHETTER · 1985 to 2026
$6.2M
Biobehavioral predictors of fatigue in newly-diagnosed breast cancer patientsR01CA160427 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOWER, JULIENNE E · 2012 to 2016
$3.2M
Behavioral and inflammatory responses to stress: Implications for depression in youth exposed to adversityK08MH112773 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KUHLMAN, KATE RYAN · 2017 to 2021
$862k
NCI NIH HHS R01 CA160427NIMH NIH HHS K08 MH112773NIMH NIH HHS T32 MH015750
6 · The paper itself

Abstract

objectiveThe aim of the study was to investigate hypothalamic-pituitary-adrenal axis (HPA axis) functioning as a neurobiological risk factor for depressive symptoms in an ongoing longitudinal, observational study of women undergoing treatment and recovery from breast cancer. Many women with breast cancer experience depressive symptoms that interfere with their treatment, recovery, and quality of life. Psychosocial risk factors for depression among patients with cancer and survivors have been identified, yet neurobiological risk factors in this population remain largely unexamined.

methodsWomen recently diagnosed with early-stage breast cancer (N = 135) were enrolled before starting neoadjuvant/adjuvant treatment (radiation, chemotherapy, endocrine therapy). At baseline, participants collected saliva samples to measure diurnal HPA axis functioning for 3 days: at waking, 30 minutes after waking, 8 hours after waking, and bedtime. Participants also completed a standardized measure of depressive symptoms (Center for Epidemiological Studies-Depression Scale) at baseline and 6 months after completion of primary treatment. Multivariate regression was used to predict continuous depressive symptoms at 6-month posttreatment from continuous depressive symptoms at baseline, cortisol awakening response (CAR), and other measures of diurnal HPA axis functioning.

resultsThe magnitude of CAR predicted changes in depressive symptoms over time, such that women with a higher CAR showed a greater increase from baseline to 6-month posttreatment (b = 5.67, p = .023). Diurnal slope and total cortisol output were not associated with concurrent depressive symptoms or their change over time.

conclusionsElevated CAR may be a neurobiological risk factor for increases in depressive symptoms in the months after breast cancer treatment and warrants further investigation.

Indexed as

AgedBreast NeoplasmsDepressionFemaleHumansHydrocortisoneHypothalamo-Hypophyseal SystemLongitudinal StudiesMiddle AgedPituitary-Adrenal SystemRisk FactorsHydrocortisone

Identifiers

PMID28570439
PMCPMC5573620
OpenAlexW2620983860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.